Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So ... light of weak durability and serious side effects, a move accompanied by a 50% ...

As an outbreak of measles infects hundreds of Americans, social media users are warning parents against the measles, mumps ...

How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.